Sun Pharma, Taro Terminate Proposed Deal

by Benzinga Staff
February 8, 2013 7:35 AM | 26 seconds read

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) and SunPharmaceutical Industries Ltd. (together with its subsidiaries, “Sun Pharma”)announced today that they have mutually agreed to terminate their mergeragreement, announced in August 2012, pursuant to which all shareholders ofTaro (other than Sun Pharma and its affiliates) would have received a cashpayment of $39.50 per share upon the closing of the merger.Each of Sun Pharma and Taro (at the direction of the Special Committee) agreedthat terminating the merger agreement was in the best interest of therespective companies and shareholders.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsM&A

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.